Piroxicam

Piroxicam (CP-16171) is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively.

Product Specifications

CAS Number

[36322-90-4]

Product Name Alternative

CP-16171

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

COX

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cancer

Assay Protocol

https://www.medchemexpress.com/piroxicam.html

Concentration

10mM

Purity

99.78

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O=C(C1=C(O)C2=CC=CC=C2S(N1C)(=O)=O)NC3=NC=CC=C3

Molecular Formula

C15H13N3O4S

Molecular Weight

331.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Kato M, et al. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001 Dec;53 (12) :1679-85.|[2]Mohammed SI, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002 Jan 15;62 (2) :356-8.|[3]Silva J, et al. Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines. Anticancer Res. 2017 Apr;37 (4) :1737-1745.